DCB Use in the Real World

A panel of experts discusses recommendations for optimizing outcomes when treating complex SFA and popliteal lesions with drug-coated balloon technology.

PARTICIPANTS

Peter A. Schneider, MD
Vascular Surgeon
Kaiser Permanente Medical Center
Honolulu, Hawaii
He has disclosed that he is on the advisory board for Medtronic plc and receives no compensation.

Prakash Krishnan, MD
Assistant Professor of Medicine
Director of Endovascular Intervention
Mount Sinai Heart
New York, New York
He has disclosed that he is a consultant to Abbott Vascular, Bard, and Covidien.

Jos C. van den Berg, MD, PhD
Service of Interventional Radiology
Ospedale Civico
 Lugano, Switzerland
He has disclosed that he has no financial interests related to this article.

Gunnar Tepe, MD
Professor of Radiology
Head of Diagnostic and Interventional Radiology
Academic Hospital RoMed Clinic of Rosenheim
Rosenheim, Germany
He has disclosed that he receives research support from and is on the Advisory Board for Medtronic plc.

Lawrence A. Garcia, MD
Section of Interventional Cardiology and Peripheral Interventions
St. Elizabeth’s Medical Center
Boston, Massachusetts
He has disclosed that he is a course director for Boston Scientific, receives research support from ev3/Covidien and Abbott/Idev Technologies, and is on the advisory board for Boston Scientific, ev3/Covidien, Spectranetics, Pathway Medical, Angiosculpt, and Abbott/Idev Technologies. He is also an equity shareholder in Scion Cardiovascular, Arsenal Medical, TissueGen Medical, Primacea, CVI Technologies, Spirox, and Essential Medical.

Krishna Rocha-Singh, MD
Associate Clinical Professor of Medicine
Prairie Heart Institute at St. John’s Hospital
Springfield, Illinois
He has disclosed that he is on the advisory board for Medtronic plc.

From the IDE to the Real World

Featuring Drs. Schneider, Rocha-Singh, Krishnan, and Tepe.

Do you believe that the IN.PACT SFA Trial data are translatable to real-world practice?

Dr. Schneider: Yes, but it is not a perfect fit for every patient who will walk through your door. There is no such thing as a successful trial with clearly measurable outcomes that will perfectly translate to everyday life.

The good news is that drug-coated balloons (DCBs) work. The pivotal trial was sizeable and was extremely well controlled and adjudicated, was carried out in a broad geographic area with many investigators of different specialties, and included lesions up to 18 cm in length, occlusions, as well as both claudication and rest
pain. In terms of pivotal trials that have been done in the past, IN.PACT SFA is as “real world” as it gets in the development of endovascular technologies. DCBs were a lot better than plain old balloon angioplasty, which we considered the standard of care not long ago.

Dr. Rocha-Singh: The clinical results obtained from a randomized, controlled, prospective, clinical trial never mirror the actual results from real-world practice. The diversion from the randomized controlled trial’s inclusion and exclusion criteria rarely reflect the clinical and angiographic patient cohorts seen in real-world practice, which is just one reason for this divergence. Additionally, it is impossible to discern the number of patients who failed entry criteria for the randomized controlled trial, as these numbers and the reasons for exclusion are rarely captured. Although I believe that the results of the IN.PACT SFA Trial are an excellent start in selecting patients who may achieve optimal results through 1 year, postmarketing surveillance trials and registry studies will capture a larger cross-section of the patient population with severe atherosclerotic femoropopliteal disease and lifestyle-limiting claudication.

**IN.PACT Global is a single-arm study evaluating a real-world population. How important is this study?**

Dr. Krishnan: I believe that the IN.PACT Global will confirm what we’ve already learned from IN.PACT SFA in a real-world population. Obviously, the lesion lengths are longer, and the inclusion/exclusion criteria are less rigid, thereby allowing us to use the IN.PACT™ Admiral™ DCB (Medtronic plc) in more difficult patients with longer lesion segments that have significantly more calcium and less runoff. This is closer to the type of patients that we treat on a day-to-day basis.

IN.PACT Global is not only going to confirm what we’ve learned from IN.PACT SFA—that the IN.PACT Admiral is effective—but it’s also going to be complementary because it will allow us to see that in real-world lesions, this balloon does work.

Dr. Rocha-Singh: Single-arm registries add to our understanding of the appropriate patient cohorts that may receive an optimal clinical benefit from this therapy. However, if patients are not consecutively enrolled in such studies, an inherent operator selection bias exists, as the physician could only enroll patients who are easiest to treat or whom they think might have the best clinical outcomes. In the IN.PACT Global Study, the sponsor enforced consecutive enrollment as much as possible in order to minimize biases in the patient selection process.

Also, the IN.PACT Global Study is independently adjudicated, which is in contradistinction to recent global registries that relied on site-directed, unadjudicated reporting of patient demographic and angiographic specifics, procedural success, complications, and primary patency through follow-up. As such, the full contribution of the IN.PACT Global Study can only be fully realized when we understand how it builds upon the results of the IN.PACT SFA Trial. Specifically, the divergence of lesion lengths, percentage of patients with “severe” calcium, length of chronic total occlusions, in-stent restenosis, TASC II C and D lesions—all were excluded from the randomized controlled trial.

Taken together, I believe that the randomized controlled trial, along with the global registry, which will include more challenging patient subsets, will provide us with a more complete assessment of the capabilities of this first-generation device and the patient cohort in which it should be applied.

**How does DCB use fit into your practice? Where are you using DCBs as your standalone therapy when treating superficial femoral artery (SFA) and popliteal lesions?**

Dr. Rocha-Singh: In general, I suspect that my use of DCBs will reflect the use of these devices by my colleagues. Clearly, patients who have failed primary angioplasty with adjunct therapies (specifically, atherectomy) will be ideal candidates for the application of the IN.PACT Admiral DCB as a standalone device.

Prof. Tepe: In the presence of heavy calcium, in Europe, we might try an adjunct therapy (cutting balloon or atherectomy) in order to prepare the vessel for better drug uptake. If there is a very long lesion, we might also use covered stent grafts, but this is very rare. I would say that most of our patients receive DCBs as the primary therapy.

Dr. Schneider: DCBs are being integrated into our practice now—our usage is increasing based upon available data. I believe that over time, the paradigm of “DCB as standalone whenever possible” will replace the paradigm of “plain old balloon angioplasty plus/minus implant” that has been our practice over the past 10 years or more. This will be a major shift in our approach. How far it goes, we don’t know. The concern is with the angioplasty mechanism itself. It is apparently good at delivering the drug; however, the acute damage caused by balloon angioplasty must be understood better. The idea that we can create extensive dissections and somehow that doesn’t matter is counterintuitive. At the very least, we need to understand what happens when dissections
are left behind. We also know that occlusions and longer lesions are more likely to require some type of scaffolding.

**In which SFA or popliteal lesions will you not use a DCB as the primary treatment option, and why?**

Dr. Schneider: We actually don’t know yet how DCBs or long subintimal angioplasty will work for heavily calcified lesions, as these types of lesions were not included in the studies that have been done to date. Patients with gangrene and those who have extensive femoropopliteal disease that could be treated with DCBs have also not been well studied in randomized controlled trials. Right now, each clinician will have to make the call in these situations.

---

**Complex Lesion Considerations**

Featuring Drs. Schneider, Garcia, Krishnan, and Rocha-Singh.

**Can you briefly explain what the term “complex lesions” means to you?**

Dr. Schneider: Complex lesions are summarized in the TASC II classification. Lesions longer than 20 cm, those that involve the common femoral artery or the popliteal artery contiguous with a long superficial femoral artery (SFA) occlusion, or those with heavy calcification are all complex, in my opinion.

Dr. Garcia: Lesions that are > 20 cm in overall length, those that have moderately heavy calcification (which again has not been well defined in the endovascular market to date), chronic total occlusions that have difficult-to-cross caps (either proximally or distally), multilevel disease in terms of inflow and outflow SFA, popliteal, and infrapopliteal disease. They can still be presenting as simple claudicants, but these are the more complex lesions that we have to deal with from day to day.

**What are some of the most common challenges of treating complex lesions in a real-world setting?**

Dr. Krishnan: The challenges of treating complex lesions depend on the morphology of the lesion. The most common complexities that we encounter are long lesions, calcific lesions, and chronic total occlusions in the femoropopliteal segment. I believe the greatest challenge now is not technical success—it is long-term patency and economic sensibility. This long-term patency was demonstrated in the IN.PACT SFA Trial patients, and I believe will be validated by the IN.PACT Global Study in a real-world setting.

The DCB has given operators the technology to maintain patency, thereby improving patient outcomes and reducing repeat procedures.

Dr. Garcia: One of the challenges is simply in crossing these lesions, but I think one of the bigger challenges we face today is the financial burdens that limit our opportunity to use all of the available tools in the more difficult cases. So, not only do you have the anatomic challenges, such as an ostial SFA lesion that extends all the way through the popliteal occlusion, which is a good 35-cm or 40-cm lesion that has moderate to heavy calcification—that’s a challenge no matter what. But then, once you’ve crossed the lesion, you also have to consider how best to treat it while keeping the cost in my hospital minimal while still providing the patient with the best outcome. In other words, is the marginal cost going to trump everything and still get the patient the best outcome, or do I have to mitigate the marginal cost in order to achieve the best outcome? The problem lies in getting those two things to come together so that you can have a good overall outcome with durability (ie, patency), but with the least amount of money out of pocket for the patient.

Dr. Rocha-Singh: Treating more complex lesions in the real-world setting will present the practicing interventionist with a significant conundrum. We do not have important outcomes data in these patients, who, in my practice, are more common; specifically, patients with severe or diffuse intimal and medial calcification, high-grade disease associated with chronic total occlusions, and small-caliber vessels with limited runoff. Typically, these patients are technically challenging, requiring the use of more adjunct technologies (multiple specialized wires, potential use of reentry devices, and use of adjuncts to angioplasty and potentially provisional nitinol stenting). These cases are longer in duration, exposing patients to increased radiation and contrast. Additionally, managing patient expectations with chal-
Challenging and complex lesions is essential, as the incidence of clinically driven target lesion revascularizations will likely be higher in these cohorts.

**What data do you still need in order to determine how to treat complex lesions?**

Dr. Schneider: I think IN.PACT Global will help with this. There are other drug-coated balloons (DCBs) in development that will also be studied, and the results of these studies will help to build our database of knowledge on these devices. In addition, there are many single-center or small multicenter studies looking at specific issues like in-stent restenosis or heavy calcification. We need to know how DCBs work in these settings. If a lesion requires scaffolding in order to achieve an acceptable posttreatment result, I believe that spot stenting and minimizing metal is best. The randomized controlled trials of DCBs were intended to understand the effect of the medication, not to answer the question of when we should stent in the setting of DCBs. That remains under consideration.

Dr. Rocha-Singh: At present, we have no peer-reviewed, appropriately powered, independently adjudicated, long-term follow-up data on the use of DCBs in complex lesions. It should be emphasized that the current technology available to us in the United States was derived from very circumscribed and well-defined patient cohorts, and we only have 1-year follow-up data. In contradistinction to bare-metal stents, we understand that the durability of nitinol stents, particularly in longer lesions, followed over 3 years, is clearly suboptimal.

We must remember that the current Lutonix (Bard Peripheral Vascular, Inc.) and Medtronic drug-coated technologies are first-generation devices, and although we have some understanding of their mechanism of action, we know little about their potential mechanisms of failure and which patients should and should not be treated with the technology. We must explore the interesting hypothesis of adjuncts to DCBs, specifically vessel pretreatment with atherectomy to maximize the potential elution of paclitaxel into the vessel wall, the impact of varying degrees of vessel wall calcification on primary patency, and their use in long occlusive disease, all which may drive the use of adjunct technologies and procedural costs.

**Is the prospect of leaving no permanent implant behind compelling?**

Dr. Krishnan: Absolutely. As we know, this is a disease process that is ongoing and unrelenting. Any permanent implant we leave behind may complicate future therapies. Mechanical implants may have structural problems such as stent fracture and in-stent restenosis, whereas DCBs allow treatment of a similar cohort of patients without these risks.

---

**Treating SFA and Popliteal Lesions With IN.PACT Admiral DCB Technology**

Featuring Drs. Schneider, Krishnan, van den Berg, Tepe, Rocha-Singh, and Garcia.

**In which patients are you most confident in using an IN.PACT Admiral DCB?**

Dr. Schneider: I believe that once the technology is widely diffused into the medical community, most patients will be candidates for DCBs for treatment of a femoropopliteal lesion. I would not recommend a DCB when it’s reasonably clear that angioplasty balloons cannot be used as standalone therapy. Patients with very heavily calcified arteries or with common femoral artery occlusive disease may not derive a benefit. Patients with in-stent restenosis and with multiple different kinds of endovascular failures will probably be treated with DCBs because we are desperate for treatment options in these patients, but we don’t yet know whether DCBs will be the best tool, nor are DCBs approved for an in-stent restenosis indication in the United States.

**What is the role of predilatation before using an IN.PACT Admiral DCB, and why is this important?**

Dr. Krishnan: That’s a very interesting question. Predilatation was mandated in the United States phase of the trial by the US Food and Drug Administration. In the United States, we predilated the lesion with a bare balloon, 1 mm less than the reference vessel diameter. The strategy being to prep the vessel in order to facilitate the delivery of paclitaxel by way of the IN.PACT Admiral DCB. We routinely perform predilatation for all DCB
cases; however, in Europe, this is not the case. In Europe, DCBs are being used without predilatation. Clinical judgment is necessary and is dependent upon lesion morphology and characteristics to determine the need for predilatation. As our experience grows in the United States, we will arrive at an algorithm for this practice as a society of endovascular interventionists.

Dr. van den Berg: Predilatation is necessary in order to prepare the vessel for optimal drug uptake into the vessel wall in a homogeneous manner. To reduce barotrauma to the vessel wall, an undersized balloon is typically used. Without predilatation, especially in total occlusions, there may be an issue of losing some of the drug while crossing a lesion that is not pretreated.

What are your strategies with regard to lesion length, predilatation balloon length, and IN.PACT Admiral DCB length, and what inflation techniques are you using?

Dr. Krishnan: In order to formulate a strategy, one must understand the nuances of DCB use. The common problems encountered are geographic miss and dissection. From the trial, we have learned the following algorithm. The lesion needs to be predilated in its entirety. Predilatation should be done using a balloon that is 1 mm < reference vessel diameter, be completed with glow tape, and then the image must be stored in the monitor. The DCB treatment balloon should be placed 10 mm distal and proximal to the location of the predilatation site to ensure avoidance of geographic miss. Predilatation also enables us to avoid under- or oversizing of the treatment balloon, thus ensuring optimal drug delivery and minimizing the occurrence of dissection. Finally, when using multiple DCBs, the balloons must overlap by at least 10 mm to avoid geographic miss.

We’re also learning about how to perform adequate balloon angioplasty. This means proper expansion of the lesion and also prolonged balloon inflation, even with predilatation. Here at Mount Sinai Heart, we recommend leaving the balloon inflated for at least a minute during predilatation, after which, we use imaging to make sure there is no flow-limiting dissection. The point here is that you want to make sure that the lesion is expanded. Once this has been confirmed, we send in the DCB and inflate to nominal pressure. We try not to go to high pressures, and then we deploy the DCB for 3 minutes in order to allow adequate entry of the drug into the vessel.

What sizing considerations do you make when using IN.PACT Admiral?

Dr. van den Berg: DCB sizing should be one to one with respect to vessel diameter.

When and how do you handle post-dilatation with a balloon after use of an IN.PACT Admiral DCB?

Prof. Tepe: Postdilatation after DCB use should be considered in cases of residual stenosis > 30%. In order to achieve good angiographic results without stenting, I very often use a shorter, uncoated balloon in the area of residual stenosis. In general, I leave this balloon inflated for 5 to 6 minutes.

When and how will stents be used along with the IN.PACT Admiral DCB?

Prof. Tepe: I use stents for spot stenting, meaning that I use stents, but I don’t cover the entire lesion with stents.

How do you prevent geographic miss? Why is this important to understand when using an IN.PACT Admiral DCB?

Dr. Rocha-Singh: The prevention of geographic miss, either within the lesion or at its margins, is essential to maximize the clinical benefit of DCBs. Before treatment, the appropriate product diameters and lengths should be available to avoid suboptimal use of the technology. Appropriate positioning of the patient’s extremity on the cath lab table and the use of the adhesive radiopaque tape applied to the index extremity to fully define the treatment zone and the radiopaque numbers is an important technique to avoid geographic miss. It is important to realize that a DCB is a balloon platform used as a drug-delivering device.

As such, appropriate understanding and expectations of a satisfactory balloon angioplasty result is essential. In this regard, many physicians who are unaccustomed with pursuing a primary angioplasty result, with or without the use of adjunct angioplasty technologies, must measure their expectations. Achieving a stent-like result is a bar too high to set, particularly in lesions excluded in the premarket approval trials. Paying close attention to minimizing any impedance to inflow and maximizing, where clinically appropriate and feasible, treatment runoff is an important concept as much as moderating expectations with regard to an acute angioplasty result after DCB use.

Dr. Krishnan: It’s important to ensure full coverage of the entire lesion; the balloon diameter must match the reference vessel diameter distal to the lesion; and the balloon length must exceed the lesion length by approximately 1 cm on both ends.
Because the acute result is often not the same as the results seen immediately after stenting, how do you manage angiographic expectations? Is positive remodeling a real consideration?

Dr. Krishnan: We have learned that vessel beautification does not correlate with positive outcomes. The IN.PACT SFA Trial demonstrated that non–flow-limiting dissections did not affect patency. We must trust in the data and not our desire for a beautiful angiographic picture.

Dr. Garcia: Being able to look into the future and imagine what the result may look like becomes critical. It is important that you can walk away from something that doesn’t look "stent-like" and understand that it will look better than a stent result at 6 months and 1 year, being able to pull back from saying, "I need to stent this," that’s when people’s experience will become most critical to being able to usher in acceptance of this tool, as well as to allow the opportunity for growth in this industry.

FOR US AUDIENCES ONLY

INDICATIONS FOR USE:

The IN.PACT Admiral Paclitaxel-Coated PTA Balloon catheter is indicated for percutaneous transluminal angioplasty, after pre-dilatation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-7 mm.

Contraindications

The IN.PACT Admiral DCB is contraindicated for use in:

- Patients who cannot receive recommended antiplatelet and/or anticoagulant therapy
- Patients judged to have a lesion that prevents complete inflation of an angioplasty balloon or proper placement of the delivery system
- Patients with known allergies or sensitivities to paclitaxel
- Women who are breastfeeding, pregnant or are intending to become pregnant or men intending to father children. It is unknown whether paclitaxel will be excreted in human milk and whether there is a potential for adverse reaction in nursing infants from paclitaxel exposure.

Warnings

- Use the product prior to the Use-by Date specified on the package.
- Contents are supplied sterile. Do not use the product if the inner packaging is damaged or opened.
- Do not use air or any gaseous medium to inflate the balloon. Use only the recommended inflation medium (equal parts contrast medium and saline solution).
- Do not move the guidewire during inflation of the IN.PACT Admiral DCB.
- Do not exceed the rated burst pressure (RBP). The RBP (14 atm [1419 kPa]) is based on the results of in vitro testing. Use of pressures higher than RBP may result in a ruptured balloon with possible intimal damage and dissection.
- The safety and effectiveness of implanting multiple IN.PACT Admiral DCBs with a total drug dosage exceeding 20.691 µg of paclitaxel in a patient has not been clinically evaluated in the IN.PACT SFA Trial.

Precautions

- This product should only be used by physicians trained in percutaneous transluminal angioplasty (PTA).
- This product is designed for single-patient use only. Do not re-use, reprocess, or re-sterilize this product. Reuse, reprocessing, or re-sterilization may compromise the structural integrity of the device and/or create a risk of contamination of the device, which could result in patient injury, illness, or death.

Potential Adverse Events

Adverse events that may occur or require intervention include, but are not limited to the following: abrupt vessel closure, access site pain, allergic reaction to contrast medium, antithrombotic therapy, or catheter system components (materials, drugs, and excipients); amputation/loss of limb; arrhythmias; arterial stenosis; arterial thrombosis; arteriovenous (AV) fistula; death; dissection; embolization; fever; hematoma; hemorrhage; hypotension/hypertension; infection; ischemia; myocardial infarction; necrosis; peripheral neuropathy.

Potential complications of peripheral balloon catheterization include, but are not limited to the following: balloon rupture, detachment of a component of the balloon and/or catheter system; failure of the balloon to perform as intended; failure to cross the lesion.

Although systemic effects are not anticipated, potential adverse events that may be unique to the paclitaxel drug coating include, but are not limited to: allergic/immunologic reaction, alopecia, anemia; gastrointestinal symptoms; hemolytic anemia; hepatic amino transferase changes; histologic changes in vessel wall, including inflammation, cellular damage, or necrosis; myalgia/arthralgia; myelosuppression; peripheral neuropathy.

Refer to the Physician’s Desk Reference for more information on the potential adverse events associated with paclitaxel. There may be other potential adverse events that are unforeseen at this time. Please reference appropriate product instructions for Use for a detailed list of indications, warnings, precautions, and potential adverse events. This content is available electronically at www.manuals.medtronic.com.

CAUTION: Federal (USA) law restricts the use of this device to sale by or on the order of a physician.